Major Depressive Disorder Clinical Trial
— TERPSISOfficial title:
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
Verified date | September 2023 |
Source | Neurocrine Biosciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
Status | Completed |
Enrollment | 93 |
Est. completion date | September 7, 2023 |
Est. primary completion date | July 7, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Key Inclusion Criteria: Participants must meet all of the following key inclusion criteria: 1. Completed written informed consent. 2. Aged 18 to 65 years, inclusive, at the time of informed consent. 3. Primary diagnosis of MDD. 4. Participants must meet one of the following criteria: - must have been taking =1 antidepressant medication(s) for =8 weeks prior to screening. - must have received =1 antidepressant medication(s) for =8 weeks in the current or most recent episode of depression. 5. Snaith Hamilton Pleasure Scale (SHAPS) score is =30 at screening and Day 1. Key Exclusion Criteria: Participants will be excluded from the study if they meet any of the following key criteria: 1. Any psychiatric disorder disallowed per protocol and electroconvulsive therapy (ECT) within 6 months prior to screening. Comorbid anxiety disorders are not exclusionary. 2. Have a significant risk of suicidal or violent behavior. 3. A history of seizure disorder, stroke, Alzheimer disease, Parkinson disease, multiple sclerosis, head injury associated with loss of consciousness for more than 15 minutes, or other neurodegenerative disorder. |
Country | Name | City | State |
---|---|---|---|
Puerto Rico | Neurocrine Clinical Site | San Juan | |
United States | Neurocrine Clinical Site | Atlanta | Georgia |
United States | Neurocrine Clinical Site | Birmingham | Alabama |
United States | Neurocrine Clinical Site | Chicago | Illinois |
United States | Neurocrine Clinical Site | Columbus | Ohio |
United States | Neurocrine Clinical Site | Dallas | Texas |
United States | Neurocrine Clinical Site | Everett | Washington |
United States | Neurocrine Clinical Site | Friendswood | Texas |
United States | Neurocrine Clinical Site | Garden Grove | California |
United States | Neurocrine Clinical Site | Houston | Texas |
United States | Neurocrine Clinical Site | Lemon Grove | California |
United States | Neurocrine Clinical Site | Murray | Utah |
United States | Neurocrine Clinical Site | Oklahoma City | Oklahoma |
United States | Neurocrine Clinical Site | Orange | California |
United States | Neurocrine Clinical Site | Orlando | Florida |
United States | Neurocrine Clinical Site | Pensacola | Florida |
United States | Neurocrine Clinical Site | Raleigh | North Carolina |
United States | Neurocrine Clinical Site | Riverside | California |
United States | Neurocrine Clinical Site | Saint Charles | Missouri |
United States | Neurocrine Clinical Site | San Diego | California |
United States | Neurocrine Clinical Site | San Francisco | California |
United States | Neurocrine Clinical Site | Skokie | Illinois |
United States | Neurocrine Clinical Site | Winter Park | Florida |
Lead Sponsor | Collaborator |
---|---|
Neurocrine Biosciences |
United States, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in anhedonia severity, as measured by change in Dimensional Anhedonia Rating Scale (DARS) score from baseline to Day 57 | Baseline, Day 57 | ||
Secondary | Change in total Montgomery Åsberg Depression Rating Scale (MADRS) score from baseline to Day 57 in participants with moderate or higher severity depression | Baseline, Day 57 | ||
Secondary | Change in Clinical Global Impression - Severity (CGI-S) score from baseline to Day 57 | Baseline, Day 57 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |